>



Sep. 2 (Thu)

ASCO/KSMO Joint Symposium 1

Integrating next-generation sequencing into clinical practices: sharing the real-world experiences
The NGS test has now become an important tool in precision medicine, and its use is also expanding in clinical practice. However, there are still issues about how to use it in the actual clinical field and in what direction in the clinical trials using it should be developed. In this session, opinions from outstanding experts from ASCO and KSMO will be heard on these issues.
Date & Time Sep. 2 (Thu), 09:00-10:30 Venue Room A
Chair
  • TBD
Presentation
Detail
  1. 1.Different tumour sequencing strategies in different clinical settings
    Lillian SIU (Princess Margaret Cancer Centre, Canada)
  2. 2.Promise and pitfall in tissue-agnostic clinical trial designs  
    Vivek Subbiah (The University of Texas MD Anderson Cancer Center, USA)
  3. 3.Challenges in clinical decision-making based on sequencing data
    Kyong Hwa PARK (Korea University Anam Hospital, Korea)
  4. Panel Discussion / Q & A

Scientific Symposium 1

Immunotherapy beyond anti-PD1/PDL1 antibody
The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) monoclonal antibodies, has changed the therapeutic landscape of some types of cancers. Despite some ICIs having manifested compelling clinical effectiveness in certain tumor types, the majority of patients still showed de novo or adaptive resistance. At present, the overall efficiency of immune checkpoint therapy remains unsatisfactory. This session will provide an opportunity to share the latest updates on new immunomodulating agents.
Date & Time Sep. 2 (Thu), 09:00-10:30 Venue Room B
Chair TBD
Presentation
Detail
  1. 1.Next-generation STING agonists that allow for IV administration
    James MOON (University of Michigan, USA)
  2. 2.Oncolytic virus immunotherapy: future prospects for oncology
    Chan KIM (CHA Bundang Medical Center, Korea)
  3. 3.TIGIT including MoA, data in the clinical trial, and insight and experience
    Melissa L JOHNSON (Sarah Cannon Research Institute, USA)
  4. 4.mRNA cancer vaccine - a new era in cancer immunotherapy
    Jeffrey S. Weber (NYU School of Medicine, USA)

Scientific Symposium 2

Resistance mechanism of immunotherapy
Recently, immune checkpoint inhibitors including PD-1 inhibitors have become standard treatments in various types of cancers. Primary or acquired resistance has significantly developed in clinical practice, and these primary and acquired resistances have a negative effect on patients' treatment outcomes. Therefore, in this session, we will conduct a comprehensive overview of the primary and acquired resistances of immunotherapy and explore the mechanisms of resistance currently being presented. We will also look at the many efforts under way and explore strategies to overcome it.
Date & Time Sep. 2 (Thu), 09:00-10:30 Venue Room C
Chair TBD
Presentation
Detail
  1. 1.Primary and Acquired Resistance to Immunotherapy
    Se-Hoon LEE (Samsung Medical Center, Korea)
  2. 2.Mechanisms of Resistance and potential combinations strategies
    Ross Andrew Soo (National University of Singapore, Singapore)
  3. 3.Window of opportunity trial with Immune Checkpoint Blockade: A Chance to Resistance mechanism
    Hye Ryun KIM (Yonsei Cancer Center, Korea)
  4. 4.Overcoming Acquired Resistance in anti-PD-1 Therapy by Simultaneously Depleting Tumor and All Major Types of Immunosuppressive cells
    Yong LU (Wake Forest School of Medicine, USA)

Plenary Lecture 1

Jedd D. Wolchok is leading melanoma and immunotherapy research at Memorial Sloan Kettering Cancer Center and is a professor of medicine at Weill Medical College of Cornell University. He led the introduction of immune checkpoint blockade to the oncology field and proposed Immune-Related Response Criteria (irRC) and Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST).
At the forefront of cancer immunotherapy and as a clinician-scientist, his recent research is focused on overcoming treatment resistance and maximizing the efficacy of immunotherapy.
Date & Time Sep. 2 (Thu), 10:50-11:30 Venue Room A
Chair TBD
Presentation
Detail
Overcoming resistance to checkpoint blockade immunotherapy
Jedd WOLCHOK (MSKCC, USA)

Scientific Symposium 9

Clinical application of ctDNA profile
Scientific symposium 9 will cover the clinical application of circulating tumor DNA (ctDNA) profiles. This includes recent application machines, reagents, and quality control issues for ctDNA analysis. Also, this session will introduce the current status of ctDNA analysis in hospital settings and specialized companies for genetic analysis in Korea. The final part will be presented as clinical application of ctDNA profiles in the perspective of the US.
Date & Time Sep. 2 (Thu), 12:40-14:10 Venue Room A
Chair TBD
Presentation
Detail
  1. 1.Analysis of ctDNA
    Seung-Tae LEE (Yonsei University College of Medicine, Korea)
  2. 2.Introduction of ctDNA panels in Korea
    Sun-Young KONG (National Cancer Center, Korea)
  3. 3.Clinical impact of ctDNA results and perspective
    Sarat CHANDARLAPATY (MSKCC, USA)
  4. Discussion: Q & A

Scientific Symposium 4

Targeting endocrine pathway: Breast & Prostate
Endocrine therapy in oncology is one of the oldest targeted therapies. In particular, endocrine therapy in breast and prostate cancer is still used as the most potent anti-tumor therapy. Moreover, the recent development of new drugs to overcome endocrine resistance has had a powerful effect on survival improvement. In this session, the development of endocrine therapy in breast and prostate cancer will be reviewed, and future treatment directions will be discussed.
Date & Time Sep. 2 (Thu), 12:40-14:10 Venue Room B
Chair TBD
Presentation
Detail
  1. 1.Progress and promise in personalized endocrine therapy in HR+ early breast cancer
    Yoon-Sim YAP (National Cancer Centre Singapore, Singapore)
  2. 2.Understanding the role of androgen receptor signaling in breast cancer
    Bora LIM (Baylor College of Medicine, USA)
  3. 3.Evolving practice in androgen-targeted therapy in prostate cancer
    Inkeun PARK (Gachon University Gil Medical Center, Korea)
  4. 4.Lighting the way forward : Castration resistant prostate cancer (CRPC)
    Jae Lyun LEE (Asan Medical Center, Korea)

Scientific Symposium 6

Recent advances in Stomach cancer & GIST
Immunotherapy has shown remarkable advances in metastatic gastric cancer and recently acquired a new FDA indication for the first-line therapy. In the anti-HER2 targeted therapy, novel game-changers are emerging one after another, and the combined effect of immunotherapy and anti-HER2 targeted therapy is also attracting significant attention.
This session talks about the latest knowledge and future development direction of immunotherapy and anti-HER2 targeted therapy in gastric cancer. In addition, an exciting talk has been prepared about GIST, which recently received approval by the FDA for the new 4th-line therapy.
Date & Time Sep. 2 (Thu), 14:30-15:30 Venue Room A
Chair TBD
Presentation
Detail
  1. 1.Current status and future perspectives of immunotherapy for gastric cancer
    Keun-Wook LEE (Seoul National University Bundang Hospital, Korea)
  2. 2.Evolution of anti-HER2 therapy for gastric cancer
    Kohei SHITARA (National Cancer Center Hospital East, Japan)
  3. 3.Promising new treatments in advanced GIST
    Hyo Song KIM (Severance Hospital, Korea)

MDT (Korean)

Treatment for brain/bone metastasis
Date & Time Sep. 2 (Thu), 14:30-15:30 Venue Room B
Chair TBD
Presentation
Detail
  1. 1.Multidisciplinary approach for patients with brain metastasis
    TBD
  2. 2.Case I : lung cancer
    TBD
  3. 3.Case II : breast cancer
    TBD

KCSG/KSMO Joint Symposium

Conducting phase I clinical trial with targeted therapy/immunotherapy
Clinical research in the oncologic field has been expanding and changing in recent years. In particular, early-stage oncologic clinical trials are conducted with precision medicine and immune-oncologic drugs under a multidisciplinary approach, moving away from the traditional approach that used only cytotoxic anticancer drugs. This session will discuss the changes and experiences in these early-stage oncology clinical trials.
Date & Time Sep. 2 (Thu), 14:30-15:30 Venue Room C
Chair
  • TBD
Presentation
Detail
  1. 1.Incorporating Precision medicine into Oncology Trials with targeted therapy and/or immunotherapy
    Chan-Young OCK (Bang&Oak Consulting, Korea)
  2. 2.Phase I clinical trial experience in the era of modern targeted and immunologic drugs
    Jonathan SUN (Norvatis Oncology, China)
  3. 3.Strategy for successful oncology trial using multidisciplinary tumor board
    Jee Hyun KIM (Seoul National University Bundang Hospital, Korea)

JSMO/KSMO Joint Symposium

Biomarker driven clinical trials : sharing experiences
This session will be a time to share strategies for successful biomarker-based clinical trials. In particular, advice from experts in each country on networking and logistics will be covered, which are important for conducting actual biomarker-based clinical trials.
Date & Time Sep. 2 (Thu), 15:50-17:20 Venue Room A
Chair
  • TBD
Presentation
Detail
  1. 1.How to select and incooperate adequate biomarkers into clinical trials
    Minkyu JUNG (Yonsei Cancer Center, Korea)
  2. 2.How to conduct biomarker driven multi-center clinical trials : networking, logistics, feasibility
    Yoshiaki NAKAMURA (National Cancer Center Hospital East, Japan)
  3. 3.Development of biomarker of IO with clinical trials
    Myung-Ju AHN (Samsung Medical Center, Korea)
  4. 4.Pharmacogenomics for biomarker of toxicities in oncology field
    Akinobu HAMADA (National Cancer Center Research Institute, Japan)

ESMO/KSMO Joint Symposium

Updates of IO Treatments and Asian subgroup analysis in oncology clinical trials
In this session, we will cover the latest insights in immuno-cancer treatments that have been successfully used alone or in combination in several settings. It will also cover the implications of individual analyses of Asian races in multinational clinical trials.
Date & Time Sep. 2 (Thu), 15:50-17:20 Venue Room B
Chair
  • TBD
Presentation
Detail
  1. 1.Summary of PAGA H & N Cancers focused on IO treatments for H & N cancers 
    Bhumsuk KEAM (Seoul National University Hospital, Korea)
  2. 2.Update of IO treatments for lung cancer
    Nicolas GIRARD (Institute Curie, France)
  3. 3.Adjuvant and neoadjuvant IO treatments for esophageal and gastric cancer
    Elizabeth SMYTH (Cambridge University Hospitals NHS Foundation Trust, UK)
  4. 4.Asian subgroup analysis in oncologic clinical trials focus on PK, PD management
    Seock-Ah IM (Seoul National University Hospital, Korea)

Scientific Symposium 5

Recent advances in NSCLC & SCLC
Scientific session 5 will deal with the latest knowledge and advances in the field of non-small cell lung cancer and small cell lung cancer. Targeted agents for EGFR mutation and ALK rearrangement, which are representative anti-cancer targets in solid tumors, are leading the development of targeted therapeutics, and a competition between existing drugs and new drugs is taking place. We would like to share with international leaders the latest knowledge and the best treatment strategies.
The treatment of small cell lung cancer had shown slow development for decades. The introduction of immune-check point inhibitors has laid the foundation for a leap forward. The attempt to newly classify small cell lung cancer can also be said to be a preparation for the future leap forward. The presentation of researchers representing Germany are anticipated.
Date & Time Sep. 2 (Thu), 15:50-17:20 Venue Room C
Chair TBD
Presentation
Detail
  1. 1.Frontline treatment strategy in advanced EGFR-mutant NSCLC
    Byoung Chul CHO (Yonsei Cancer Center, Korea)
  2. 2.The arena of TKIs: optimal treatment sequence in ALK-positive advanced NSCLC
    Dong-Wan KIM (Seoul National University Hospital, Korea)
  3. 3.BIologic updates in SCLC: molecular profiling and biomarkers
    Martin SEBASTIAN (University Hospital Frankfurt, Germany)
  4. 4.Evolving treatment paradigms for first-line extensive stage SCLC
    Niels REINMUTH (Asklepios Lung Clinic, Germany)

Plenary Lecture 2

Giuseppe Curigliano, is an associate professor of medical oncology at the University of Milano and head of the Division of Early Drug Development at the European Institute of Oncology, IRCCS, Italy. He is a renowned researcher specializing in early drug development and breast cancer clinician. He is also serving as a chair, organizer, and faculty member in various meetings in the oncology and breast cancer field.
Recently, he went through and overcame the COVID-19 pandemic in Northern Italy and proposed guidelines for continuing care and research for cancer patients. As a plenary speaker, he will share his insights and vision for patient care and research in the pandemic era.
Date & Time Sep. 2 (Thu), 17:20-18:00 Venue Room A
Chair TBD
Presentation
Detail
Sharing experiences and establishment of guidelines of cancer care in COVID-19 pandemic
Giuseppe CURIGLIANO (University of Milano, Italy)